IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.

Objective: Type 2 diabetes mellitus (T2DM) is a risk factor for nonalcoholic fatty liver disease (NAFLD). The aim of this study was to investigate the effect of T2DM on nonalcoholic steatohepatitis (NASH) and advanced fibrosis. Methods: A total of 221NAFLD patients who had undergone a liver biopsy were included in this study. Subjects were divided into a non-T2DM group and a T2DM group based on glycemic control. NASH was diagnosed by the joint presence of steatosis, ballooning and lobular inflammation. The steatosis, activity and fibrosis score (SAF) and NAFLD activity score (NAS) were used to evaluate the severity of NAFLD. The severity of liver fibrosis was evaluated based on the fibrosis stage. Results: The total percentagesof NASH and advanced fibrosis in this study were 95.0% and 50.2%, respectively. The percentages of NASH and advanced fibrosis in NAFLD patients with T2DM were 96.1% and56.5%, respectively, which were higher than those in the non-T2DM group. SAF (especially activity and fibrosis stage) and NAS (especially ballooning) were higher in NAFLD patients with T2DM than in NAFLD patients without T2DM. Glycemic control and insulin resistance were positively associated with SAF, NAS, and fibrosis stage. Additionally, T2DM elevated the risk of a high NAS and advanced fibrosis. Conclusion: T2DM increases the risk of serious NASH and advanced fibrosis in patients with NAFLD. Liver biopsy can be performed in NAFLD patients with T2DM to confirm the stage of NAFLD. Screening of NASH and advanced fibrosis in NAFLD patients with T2DM is needed.

[1]  C. Mantzoros,et al.  Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. , 2019, Metabolism: clinical and experimental.

[2]  E. Dirinck,et al.  The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity , 2019, Front. Immunol..

[3]  A. Lonardo,et al.  A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue? , 2018, Acta Diabetologica.

[4]  R. Clarke,et al.  Diabetes, Plasma Glucose, and Incidence of Fatty Liver, Cirrhosis, and Liver Cancer: A Prospective Study of 0.5 Million People , 2018, Hepatology.

[5]  L. Ye,et al.  Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus , 2017, Medicine.

[6]  A. Lonardo,et al.  Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. , 2017, Metabolism: clinical and experimental.

[7]  K. Watt,et al.  Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic , 2017, Hepatology.

[8]  K. Cusi,et al.  Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action , 2017, Diabetes Care.

[9]  K. Cusi,et al.  Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus. , 2016, Endocrinology and metabolism clinics of North America.

[10]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[11]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[12]  C. Byrne,et al.  Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[13]  A. S. Al-Goblan,et al.  Mechanism linking diabetes mellitus and obesity , 2014, Diabetes, metabolic syndrome and obesity : targets and therapy.

[14]  P. Bedossa.  Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease , 2014, Hepatology.

[15]  K. Cusi,et al.  Role of Insulin Resistance and Diabetes in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease , 2014, Current Hepatology Reports.

[16]  Eliseo Guallar,et al.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. , 2013, American journal of epidemiology.

[17]  A. Lonardo,et al.  Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[18]  L. Adams,et al.  A prospective evaluation of the role of transient elastography for the detection of hepatic fibrosis in type 2 diabetes without overt liver disease , 2012, Scandinavian journal of gastroenterology.

[19]  V. Basevi,et al.  Standards of Medical Care in Diabetes—2012 , 2011, Diabetes Care.

[20]  L. Adams,et al.  Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment , 2011, Nature Reviews Endocrinology.

[21]  V. Pannain,et al.  Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[22]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[23]  E. Brunt.  Histopathology of non-alcoholic fatty liver disease. , 2009, Clinics in liver disease.

[24]  N. Bhala,et al.  Non-alcoholic fatty liver disease , 2009, BMJ : British Medical Journal.

[25]  B. Neuschwander‐Tetri,et al.  Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD—Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network , 2009, Hepatology.

[26]  Joshi,et al.  Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. , 2009, The Journal of the Association of Physicians of India.

[27]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[28]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[29]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[30]  D. Amarapurkar,et al.  Non‐alcoholic steatohepatitis in type 2 diabetes mellitus , 2004, Journal of gastroenterology and hepatology.

[31]  M. Kaplan,et al.  Evaluation of abnormal liver-enzyme results in asymptomatic patients. , 2000, The New England journal of medicine.

[32]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[33]  N. Patel,et al.  Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. , 2006, Annals of hepatology.